Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.48 |
| ▸ | GSK3B | P49841 | 10/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | WNT1 | P04628 | 4/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28268277 | 0.89 | ABL1 (0.58) | ROCK2ABL1KITPIK3C3CCNT1 | |
| SCHEMBL25090827 | 0.81 | KLKB1 (0.47) | ROCK2ABL1ACKR3 | |
| SCHEMBL28269935 | 0.79 | ABL1 (0.48) | ABL1KITCCNT1CDK9 | |
| SCHEMBL4006198 | 0.78 | ROCK2 (0.68) | ROCK2ABL1 | |
| SCHEMBL30409311 | 0.76 | CHRM5 (0.64) | — | |
| SCHEMBL26347705 | 0.76 | CHRM5 (0.64) | — | |
| SCHEMBL26944401 | 0.76 | ALDH1A1 (0.54) | ABL1DYRK1AGSK3BCCNT1CCNE1 | |
| SCHEMBL28268323 | 0.74 | POLB (0.54) | — | |
| SCHEMBL28268321 | 0.74 | POLB (0.54) | — | |
| SCHEMBL3499511 | 0.73 | KIT (0.61) | ROCK2KITPIK3C3CCNT1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | claimed |
| EP-1960399-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Pfizer Italia S.r.l. (IT) | 2008-08-27 | — | — | EP | disclosed |
| US-7371862-B2 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2008-05-13 | — | — | US | disclosed |
| WO-2007054508-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K6, MAP3K1 | ROCK2 575/4885ABL1 166/4885KIT 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.